Driehaus Capital Management LLC purchased a new position in Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report) during the second quarter, HoldingsChannel.com reports. The fund purchased 66,667 shares of the company’s stock, valued at approximately $1,174,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Sandia Investment Management LP bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $88,000. Rhumbline Advisers bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $118,000. Bank of New York Mellon Corp bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $356,000. Squarepoint Ops LLC bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $2,642,000. Finally, Versant Venture Management LLC bought a new position in shares of Contineum Therapeutics in the second quarter worth approximately $16,169,000.
Wall Street Analysts Forecast Growth
Separately, Royal Bank of Canada raised their price target on Contineum Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 14th.
Contineum Therapeutics Stock Up 0.9 %
Shares of Contineum Therapeutics stock opened at $18.84 on Monday. The firm’s fifty day moving average price is $18.73. Contineum Therapeutics, Inc. has a 12 month low of $13.27 and a 12 month high of $22.00.
Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.02). Sell-side analysts anticipate that Contineum Therapeutics, Inc. will post -2.04 EPS for the current year.
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
Featured Articles
- Five stocks we like better than Contineum Therapeutics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 9/23 – 9/27
Want to see what other hedge funds are holding CTNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report).
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.